Home | GSK US
January 07 2025 GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
Company | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
Press releases - GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation …
Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, …
Products - GSK US
Our portfolio of more than 20 marketed vaccines is one of the industry’s broadest. We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at …
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for …
US FDA accepts GSK’s submission for the use of Nucala …
Dec 9, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review …
Gepotidacin accepted for priority review by US FDA for treatment …
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for gepotidacin, an investigational, first-in-class …
Search jobs - GSK US
Explore our career opportunities all over the world
At a glance - GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US Our largest US-based operation, the …